Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults
详细信息 查看全文
- 作者：Robert J. Hopkinsa ; hopkinsr@ebsi.com" class="auth_mail" title="E-mail the corresponding author ; Gurdyal Kalsia ; 1 ; Victor M. Montalvo-Lugoa ; Mona Sharmaa ; Yukun Wua ; Derek D. Museb ; Eric A. Sheldonc ; Frank C. Hampeld ; Laurence Lemialea
- 关键词：NCT01770743
- 刊名：Vaccine
- 出版年：2016
- 出版时间：19 April 2016
- 年：2016
- 卷：34
- 期：18
- 页码：2096-2105
- 全文大小：2300 K
文摘
- •
AV7909 is a combination of BioThrax® (Anthrax Vaccine Absorbed) and CPG 7909 adjuvant.
- •
AV7909 vaccine is being developed for anthrax post-exposure prophylaxis.
- •
The safety and immunogenicity of 2 doses and 3 vaccine schedules were evaluated.
- •
Immunogenicity results indicate further study of a two dose schedule is warranted.
- •
Both doses and all vaccine schedules were well tolerated.